Astrazeneca Plc ADR (AZN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 09-2024 | 06-2024 | 03-2024 | 12-2023 | 09-2023 | |
| Sales | 13,565,000 | 12,938,000 | 12,679,000 | 12,024,000 | 11,492,000 |
| Cost of Goods | 3,081,000 | 2,183,000 | 2,218,000 | 2,308,000 | 2,095,000 |
| Gross Profit | 10,484,000 | 10,755,000 | 10,461,000 | 9,716,000 | 9,397,000 |
| Operating Expenses | 8,378,000 | 8,009,000 | 7,346,000 | 8,482,000 | 7,443,000 |
| Operating Income | 2,106,000 | 2,746,000 | 3,115,000 | 1,234,000 | 1,954,000 |
| Interest Expense | 457,000 | 443,000 | 413,000 | 438,000 | 392,000 |
| Other Income | 179,000 | 94,000 | 98,000 | 101,000 | 90,000 |
| Pre-tax Income | 1,828,000 | 2,397,000 | 2,800,000 | 897,000 | 1,652,000 |
| Income Tax | 395,000 | 469,000 | 620,000 | -62,000 | 274,000 |
| Net Income Continuous | 1,433,000 | 1,928,000 | 2,180,000 | 959,000 | 1,378,000 |
| Minority Interests | 4,000 | 1,000 | N/A | N/A | 4,000 |
| Net Income | $1,429,000 | $1,927,000 | $2,180,000 | $959,000 | $1,374,000 |
| EPS Basic Total Ops | 0.46 | 0.62 | 0.70 | 0.31 | 0.45 |
| EPS Basic Continuous Ops | 0.46 | 0.62 | 0.70 | 0.31 | 0.44 |
| EPS Diluted Total Ops | 0.46 | 0.62 | 0.70 | 0.30 | 0.44 |
| EPS Diluted Continuous Ops | 0.46 | 0.62 | 0.70 | 0.30 | 0.44 |
| EPS Diluted Before Non-Recurring Items | N/A | 0.99 | 1.03 | 0.73 | 0.87 |
| EBITDA(a) | $3,923,000 | $4,025,000 | $4,370,000 | $2,561,000 | $3,236,000 |